These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29556695)

  • 1. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
    Kim DW; Saussele S; Williams LA; Mohamed H; Rong Y; Zyczynski T; Pinilla-Ibarz J; Abruzzese E
    Ann Hematol; 2018 Aug; 97(8):1357-1367. PubMed ID: 29556695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
    Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
    Jain AG; Gesiotto Q; Ball S; Nodzon L; Rodriguez A; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman DA; Lancet JE; Pinilla-Ibarz J; Sweet K
    Ann Hematol; 2024 Jun; 103(6):1941-1945. PubMed ID: 38634915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
    Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
    Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
    Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
    Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERN.
    Cortes JE; Jiang Q; Wang J; Weng J; Zhu H; Liu X; Hochhaus A; Kim DW; Radich J; Savona M; Martin-Regueira P; Sy O; Saglio G
    Haematologica; 2024 Oct; 109(10):3251-3260. PubMed ID: 38695123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
    Cortes JE; Lipton JH; Miller CB; Busque L; Akard LP; Pinilla-Ibarz J; Keir C; Warsi G; Lin FP; Mauro MJ
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):286-96. PubMed ID: 26993758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
    Cortes JE; Saglio G; Kantarjian HM; Baccarani M; Mayer J; Boqué C; Shah NP; Chuah C; Casanova L; Bradley-Garelik B; Manos G; Hochhaus A
    J Clin Oncol; 2016 Jul; 34(20):2333-40. PubMed ID: 27217448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
    Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.
    Cortes JE; Jiang Q; Wang J; Weng J; Zhu H; Liu X; Hochhaus A; Kim DW; Radich J; Savona M; Martin-Regueira P; Sy O; Gurnani R; Saglio G
    Leukemia; 2020 Aug; 34(8):2064-2073. PubMed ID: 32265500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
    Scalzulli E; Caocci G; Efficace F; Rizzo L; Colafigli G; Di Prima A; Pepe S; Fegatelli DA; Carmosino I; Diverio D; Latagliata R; La Nasa G; Martelli M; Foà R; Breccia M
    Ann Hematol; 2021 May; 100(5):1213-1219. PubMed ID: 33677654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors.
    Okamoto S; Ureshino H; Kawaguchi A; Miyazono M; Ikeda Y; Kimura S
    Int J Hematol; 2020 Jul; 112(1):41-45. PubMed ID: 32306183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
    Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
    Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
    BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
    Hehlmann R; Cortes JE; Zyczynski T; Gambacorti-Passerini C; Goldberg SL; Mauro MJ; Michallet M; Simonsson B; Williams LA; Gajavelli S; DeGutis I; Sen GP; Paquette RL
    Am J Hematol; 2019 Jan; 94(1):46-54. PubMed ID: 30290003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
    Murai K; Yamaguchi K; Ito S; Miyagishima T; Shindo M; Wakasa K; Inomata M; Nagashima T; Kondo T; Fujimoto N; Yamamoto S; Yonezumi M; Oyake T; Kowata S; Tsukushi Y; Mine T; Meguro K; Ikeda K; Watanabe R; Saito S; Sato S; Tajima K; Chou T; Kubo K; Oba K; Sakamoto J; Ishida Y;
    Eur J Haematol; 2018 Jan; 100(1):27-35. PubMed ID: 28895203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
    Sasaki K; Kantarjian H; Jabbour E; Ravandi F; Takahashi K; Konopleva M; Borthakur G; Garcia-Manero G; Wierda W; Daver N; Jain P; Satta T; Pierce S; Rios MB; Cortes JE
    Haematologica; 2016 Aug; 101(8):e324-7. PubMed ID: 27175025
    [No Abstract]   [Full Text] [Related]  

  • 19. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
    Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
    Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.
    Bostan H; Toptas T; Tanrikulu FP; Kut K; Arikan F; Yilmaz F; Atagunduz I; Firatli-Tuglular T
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):836-842. PubMed ID: 32958432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.